UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

March 22, 2023

Amy L. Cummings, MD, discusses the significance of the phase 3 FLAURA trial evaluating osimertinib in locally advanced or metastatic non–small cell lung cancer (NSCLC).

March 20, 2023

Edward B. Garon, MD, MS, discusses the use of PD-L1 inhibitor and CTLA-4 inhibitor combinations in non–small cell lung cancer.

March 10, 2023

Jeremie Calais, MD, MSc, discusses the role of prostate-specific membrane antigen-PET imaging in metastatic-castrate resistant prostate cancer, and touches on the importance of integrating PSMA-PET imaging into community settings for clinical practice.

March 10, 2023

Matthew Rettig, MD, discusses the evolution of triplet therapy within the landscape of metastatic hormone-sensitive prostate cancer, as well as the importance of considering key prognostic factors when utilizing this approach.

March 09, 2023

Zev A. Wainberg, MD, discusses the rationale behind the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

March 09, 2023

Despite incremental advances in the treatment landscape of metastatic colorectal cancer, patients with the disease still face a poor prognosis.

March 07, 2023

Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.

February 28, 2023

Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.

February 28, 2023

Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.

February 21, 2023

Matthew Rettig, MD, discusses emerging treatment options for patients with stage IV metastatic prostate cancer and highlights key data from clinical trials in the space.

February 21, 2023

Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.

February 21, 2023

Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.

February 08, 2023

Bartosz Chmielowski, MD, discusses the rationale for IGNYTE, the unique mechanism of action of RP1, and how melanoma research is seeking to determine treatments for patients based on their individual resistance mechanisms.

February 07, 2023

Bartosz Chmielowski, MD, discusses the current treatment landscape of metastatic melanoma.

February 01, 2023

Drew Moghanaki, MD, MPH, discusses questions that still need to be addressed following the phase 3 CheckMate-816 trial of the neoadjuvant combination nivolumab plus chemotherapy in patients with non–small cell lung cancer.

February 01, 2023

J. Randolph (Randy) Hecht, MD, discusses the investigation of XL092 plus atezolizumab in patients with microsatellite stable/microsatellite instability–low metastatic colorectal cancer.

January 31, 2023

Edward B. Garon, MD, MS, describes research combining angiogenesis and PD-1/PD-L1 inhibition stemming from the phase 3 IMpower150 trial in patients with metastatic nonsquamous NSCLC.

January 30, 2023

Amar U. Kishan, MD, discusses interim results from the phase 3 MIRAGE trial of magnetic resonance imaging–guided stereotactic body radiotherapy in prostate cancer.

December 29, 2022

Ritu Salani, MD, MBA, discusses the continued evolution of molecular profiling in endometrial cancer, advances in immunotherapy for endometrial and cervical cancer, and ongoing research in gynecologic cancers.

December 08, 2022

Sara A. Hurvitz, MD, discusses sequencing therapeutic options for patients with HER2-positive breast cancer.